American Journal of Physiology-Endocrinology and Metabolism · 2004 · 90 citations · 56 references
Life SciencesEndocrinologyPharmacologyCellular MetabolismMetabolic RegulationMetabolismAdipose TissueHormonal Control Of MetabolismSteroid Hormone BiochemistrySteroid MetabolismSteroidogenesis RegulationSteroidogenic Enzymes11 Beta-hydroxysteroid DehydrogenaseBlood Glucose RegulationGlucocorticoid Mechanism Of ActionGlucocorticoid Regulation Of MetabolismHydroxysteroid DehydrogenasesPeroxisome Proliferator-activated Receptor Gamma AgonismPeroxisome Proliferator-activated Receptor Gamma RegulationPeroxisome Proliferator-activated Receptor Signaling
Dehydroepiandrosterone (DHEA) exerts beneficial effects on blood glucose levels and insulin sensitivity in obese rodents and humans, resembling the effects of peroxisome proliferator-activated receptor-gamma (PPARgamma) ligands and opposing those of glucocorticoids; however, the underlying mechanisms remain unclear. Glucocorticoids are reactivated locally by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which is currently considered as a promising target for the treatment of obesity and diabetes. Using differentiated 3T3-L1 adipocytes, we show that DHEA causes downregulation of 11beta-HSD1 and dose-dependent reduction of its oxoreductase activity. The effects of DHEA were comparable with those of the PPARgamma agonist rosiglitazone but not additive. Furthermore, DHEA reduced the expression of hexose-6-phosphate dehydrogenase, which stimulates the oxoreductase activity of 11beta-HSD1. These findings were confirmed in white adipose tissue and in liver from DHEA-treated C57BL/6J mice. Analysis of the transcription factors involved in the DHEA-dependent regulation of 11beta-HSD1 expression revealed a switch in CCAAT/enhancer-binding protein (C/EBP) expression. C/EBPalpha, a potent activator of 11beta-HSD1 gene transcription, was downregulated in 3T3-L1 adipocytes and in liver and adipose tissue of DHEA-treated mice, whereas C/EBPbeta and C/EBPdelta, attenuating the effect of C/EBPalpha, were unchanged or elevated. Our results further suggest a protective effect of DHEA on adipose tissue by upregulating PPARalpha and downregulating leptin, thereby contributing to the reduced expression of 11beta-HSD1. In summary, we provide evidence that some of the anti-diabetic effects of DHEA may be caused through inhibition of the local amplification of glucocorticoids by 11beta-HSD1 in adipose tissue.
56
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
John C. Yoon, Pere Puigserver, Guoxun Chen et al. · Nature · 2001 · 1.8K citations
A Transgenic Model of Visceral Obesity and the Metabolic Syndrome
Hiroaki Masuzaki, J. Paterson, Hiroshi Shinyama et al. · Science · 2001 · 1.8K citations
Yuri Kotelevtsev, Megan C. Holmes, Ann N. Burchell et al. · Proceedings of the National Academy of Sciences · 1997 · 855 citations
11β-Hydroxysteroid Dehydrogenase
Paul M. Stewart, Zygmunt S. Krozowski · Vitamins and hormones · 1997 · 715 citations